# data[].attributes.body
It is a genetic disorder, passed from parent to child, when the kidneys grow fluid filled sacs on them. There is currently no treatment or cure for polycystic kidney disease.

# data[].attributes.attachment_link.readable_text
In patients with polycystic kidney diseases (PKDs), the kidneys contain multiple fluid-filled cysts, although other organs may also be affected (). Although PKD is inherited monogenically, it is phenotypically, genically and allelically heterogeneous. Autosomal dominant PKD (ADPKD) is the most common form of PKD and is generally an adult-onset, multisystem disorder that is characterized by gradually growing renal cysts that start to develop in utero and can originate from all areas of the kidneys, although cysts usually form in the distal regions of the nephron and the collecting duct. Progressive fibrocystic renal disease in ADPKD is often accompanied by hepatobiliary changes or other extrarenal abnormalities, such as intracranial arterial aneurysms. Mutations in PKD1 or PKD2, which encode polycystin 1 (PC1) and PC2, respectively, are the most common cause of ADPKD. PC1 and PC2 form a heterodimeric complex through the interaction of the coiled-coil motifs in the carboxy-terminal tails of each protein, which likely functions at primary cilia. PC2 is a cation channel that is a member of the transient receptor potential (TRP) family of ion channels, which are ubiquitously present across evolution and usually contain six membrane-spanning helices that are flanked by an intracellular amino terminus and carboxyl terminus (). By contrast, the roles of PC1 and the PC1-PC2 complex are only poorly understood. Autosomal recessive PKD (ARPKD) is rarer, and the clinical course is usually much more severe than with ADPKD. ARPKD typically manifests perinatally or in childhood, and patients often die perinatally or in infancy. Manifestations of the disease include hepatic fibrosis and greatly enlarged kidneys, and cysts typically affect the collecting ducts. ARPKD is primarily caused by mutations in polycystic kidney and hepatic disease 1 ( PKHD1), which encodes fibrocystin (also known as polyductin), a protein that localizes to the primary cilium and basal body.

Although single renal cysts are common and usually benign in adults, bilateral cystic kidneys require careful clinical assessment to identify the underlying genetic disorder, especially in children, owing to major implications for the patient and family. Both ADPKD and ARPKD often result in chronic kidney disease (CKD; a gradual loss of kidney function) and end-stage renal disease (ESRD; severe kidney disease that requires dialysis or kidney transplantation for patient survival), which are associated with substantial associated morbidity and mortality.

In the past decade, progress has been made in unravelling the aetiology of PKD. Studies have shown that the proteins encoded by genes associated with PKD colocalize in multimeric complexes at distinct subcellular sites in epithelial cells, and compelling evidence exists to suggest that primary cilia have a central pathogenic role in PKD. Cell biological and clinical research approaches have further extended our understanding of the pathophysiology of PKD and are starting to help in the identification of rational personalized therapies.

In this Primer, we provide a general overview of the current knowledge of ADPKD and ARPKD, including the epidemiology, pathophysiology, prevention, prognosis and quality of life (QOL). Furthermore, we discuss the diagnostic approaches and the clinical management of PKD and its comorbidities in greater detail. Finally, we provide a brief outlook and discuss potential future therapeutic options.

Epidemiology

ADPKD

ADPKD is the most common potentially lethal (that is, it results in renal failure and death in the absence of renal replacement therapy (RRT)) single-gene disorder and the most prevalent inherited progressive kidney disease. The prevalence of ADPKD is reported to be between 1 in 400 and 1 in 1,000 live births, mainly on the basis of two early landmark clinical studies, in Denmark and in Minnesota, USA. On the basis of this prevalence, ADPKD is predicted to affect >10 million people worldwide in all ethnic groups and therefore constitutes a major public health burden.

To ascertain the exact prevalence of a hereditary disease, several factors must be considered - the geographic and ethnic composition and the size of the population, the choice and mode of calculation of epidemiologic measurement, the screening policies and other characteristics of the health-care system, the disease definition and diagnostic criteria that are used, the sources of ascertainment and possible causes of under-ascertainment and the period of time during which events are counted (ascertainment period). Thus, variability in study design and ascertainment might partially explain the large differences in estimates of the prevalence of ADPKD that have been reported in some studies. For example, two clinical surveys in Europe (carried out in the United Kingdom and in France), as well as a survey in the Seychelles measured the prevalence of symptomatic individuals and estimated the prevalence of asymptomatic individuals. The estimated prevalence of ADPKD was 1 in 2,459 in the UK study, 1 in 1,111 in the French study and 1 in 542 for the Seychelles. In the study of the Seychelles population, the researchers speculated that the high prevalence among white individuals might be due to a founder effect (that is, low genetic variation in a population because it was started by a small number of individuals).

Subsequent studies based on renal phenotypic features reported an ADPKD prevalence of 1 in 2,700 to 1 in 4,000 in different populations in Europe and Japan. A recent study on ADPKD prevalence in the European Union, which reviewed the epidemiology literature from 1980 to 2015 and was based mainly on the large Registry of the European Renal Association (ERA)-European Dialysis and Transplant Association (EDTA), estimated that the prevalence of ADPKD in 19 countries was 1 in 2,525 (REF.); that is, fewer than 5 cases in 10,000, which is the threshold for a rare disease in the European Union.Importantly, the prevalence rates estimated in all these studies were much lower than the ADPKD prevalence estimated from autopsy studies (≥1 in 500). These data suggest that marked under-ascertainment exists and that a considerable number of (probably only mildly or moderately) affected individuals remain undiagnosed.

ADPKD is an important cause of ESRD, for which patients receive RRT, which includes haemodialysis, peritoneal dialysis, haemofiltration, haemodiafiltration and kidney transplantation. In a population-based registry in Germany, 32% of patients with ADPKD were receiving RRT. ESRD occurs as a result of ADPKD in up to 75% of patients by 70 years of age. Age-adjusted sex ratios suggest that ADPKD is more progressive in men than in women (1.2-1.3 men to women) on the basis of rates of ESRD. A Canadian study reported that 25% of patients with ADPKD had ESRD by 47 years of age, 50% by 59 years of age and 75% by 70 years of age. In a French study, 22% of patients with ADPKD had ESRD by 50 years of age, 42% by 58 years of age and 72% by 73 years of age. A European study of >300,000 patients starting RRT between 1991 and 2010 reported that the age-adjusted and sex-adjusted incidence of RRT in patients with ADPKD increased slightly over the study period from 7.6 per million to 8.3 per million population. The researchers in this study noted that the incidence of RRT had markedly increased over time in patients >70 years of age, whereas no change was observed for the cohort of patients with ADPKD who were <50 years of age, suggesting that older patients are receiving RRT. In the UK Renal Registry, mortality in patients with ADPKD receiving RRT was 3.18-4.96 per 100 person-years, which was lower than that of patients receiving RRT who had other renal diseases. The ADPKD group had a lower hazard for all-cause mortality than the other renal diseases group (adjusted HR 0.45, 95% CI 0.38-0.53). Cardiac diseases and infections were the leading causes of death in patients with ADPKD who received RRT.

ARPKD

As ARPKD is much rarer than ADPKD, the available epidemiological data for ARPKD are not as extensive as those for ADPKD. The reported incidence of ARPKD in North, Central and South America is 1 in 26,500 live births, corresponding to a carrier frequency of ~1 in 70 in non-isolated populations. Isolated or inbred populations with many consanguineous marriages might have a much higher prevalence - an incidence of 1 in 8,000 births in Finland was reported. Boys and girls seem to be equally affected by ARPKD. Of note, among children with PKD in paediatric nephrology departments, the total number of patients with early-onset ADPKD might be comparable to the number of children with ARPKD. The overall prevalence of PKD in children is estimated to be ~1 in 10,000.

After delivery, the pulmonary status of neonatal infants usually dictates a requirement for early disease management of ARPKD. Mortality of 30-40% due to pulmonary hypoplasia has been reported for ARPKD. However, for infants who survive the perinatal period, the long-term prognosis for patient survival is much better than generally perceived by many medical professionals. One-year and 10-year survival are ~85% and ~82%, respectively.

Mechanisms/pathophysiology

The polycystin proteins are localized predominantly, although not exclusively, in the primary cilium, which is a hair-like structure that protrudes from the apical membrane of renal epithelial cells into the lumen of the nephron. The distribution of the polycystin proteins at different subcellular locations is required for them to orchestrate a network of signalling pathways that establish and maintain a differentiated renal epithelium.

ADPKD

Genes and proteins.

Mutations in PKD1 (chromo-some 16p13.3) are responsible for almost 80% of cases of ADPKD, whereas ~15% of ADPKD cases are attributed to mutations in PKD2 (chromosome 4q22.1) and the remaining ~5-10% of ADPKD cases are genetically unresolved or are due to rare mutations in other loci. These rare mutations that result in an ADPKD-like phenotype occur in hepatocyte nuclear factor 1β ( HNF1B; which is a transcription factor that upregulates the expression of multiple PKD-associated genes, including PKHD1 and PKD2), neutral α-glucosidase AB ( GANAB; which is involved in protein folding) and DNAJB11 (which encodes a chaperone protein that is associated with binding-immunoglobulin protein (BiP; also known as HSPA5)). In addition, ADPKD can result from mutations in genes that are primarily associated with autosomal dominant polycystic liver disease (ADPLD), including SEC63 (which encodes a protein that is required for protein translocation across the endoplasmic reticulum (ER) membrane) and PRKCSH (which encodes the regulatory β-subunit of glycosidase 2 that is involved in protein folding). Patients with mutations in GANAB can manifest with an ADPKD or ADPLD phenotype, and other possible ADPLD-causing genes include LRP5 (which encodes a WNT co-receptor), ALG8 (which encodes an α−1,3-glucosyltransferase) and SEC61B (which encodes the β-subunit of the SEC61 trans-locon). Carriers with a mutation in one PKHD1 allele may also sometimes manifest with a few liver or kidney cysts. In addition, autosomal dominant tubulointer-stitial kidney disease (ADTKD) caused by mutations in uromodulin ( UMOD), mucin 1 ( MUC1), renin ( REN) and SEC61A (which encodes the α-subunit of the SEC61 translocon) can also sometimes be mistaken for ADPKD, although ADTKD is usually associated with renal impairment without renal enlargement and with only a few cysts. Mutations in COL4A1 (which encodes a collagen subunit), including those associated with hereditary angiopathy with nephropathy, aneurysms and muscle cramps (HANAC) syndrome, can sometimes cause an ADPKD-like phenotype. The X-linked ciliopathy caused by mutations in OFD1 (which encodes a centriole and centriolar satellite protein and is associated with oral-facial-digital syndrome type I) can also sometimes be confused with ADPKD, although additional facial and digital phenotypes are usually present. In summary, mutations in PKD1 and PKD2 are the main cause of ADPKD, but mutations that interfere with the biogenesis of PC1, reduce the expression of PKD1 or PKD2 or ciliopathy and other mutations can sometimes mimic ADPKD. ADPKD can sometimes also be mimicked by the hereditary cancer syndromes tuberous sclerosis and von Hippel-Lindau syndrome in cases in which extrarenal features are either absent or mild.

PC1 is a large, integral membrane protein of 4,303 amino acids with 11 transmembrane domains, an extensive extracellular domain containing multiple predicted motifs and a small, ~200-amino acid intracellular carboxy-terminal tail that regulates multiple signalling cascades (). PC1 is cleaved at the G protein-coupled receptor proteolytic site to generate a large amino-terminal fragment that remains non-covalently tethered to the carboxy-terminal fragment at the plasma membrane. This cleavage seems to regulate the biogenesis and trafficking of PC1 (REF.). In addition, regulated cleavage of the intracellular C-terminal tail releases PC1 fragments into the cytoplasm, which translocate to the nucleus and interact with transcription activators, repressors and co-activators to modulate various signalling pathways.

Although many of the functions of PC1 remain unclear, the C-terminal tail of PC1 is known to mediate the interaction of PC1 with PC2 (REF.), which is involved in the regulation of ion transport and indirectly affects Ca ²⁺ signalling. The cryo-electron microscopy structure of PC2 establishes it as a homotetrameric ion channel, although it is possible that PC2 heteromultimerizes with other TRP channel subunits or with PC1 (REFS).

Patients with ADPKD usually carry a germline mutation in one allele of either PKD1 or PKD2 (see Diagnosis section, below), although at least one second event, such as somatic inactivation of the remaining wild-type PKD1 or PKD2 allele or loss of heterozygosity, is required to initiate cyst formation. In addition, variants in other genes linked to PKD or unidentified modifying genes, as well as environmental factors such as acute kidney injury, can modulate cyst formation and disease progression. The likelihood of cyst formation substantially increases when the level of functional PC1 or PC2 drops below a critical threshold; accordingly, the amount of functional PC1 or PC2 and, thereby, the type of mutation (for example, inactivating mutations or mutations that reduce the function of the gene product (hypomorphic mutations)) affect the likelihood of cyst formation and the disease progression (). In mice, disruption of Pkd1 in a small number (10%) of cells leads to an ~6-month dormant period in which there is no renal tubular dilatation, followed by a period with rapid cyst formation, suggesting that additional triggers are required to initiate cyst formation.

Determinants of disease severity.

The renal phenotype in patients with ADPKD ranges from patients in old age without renal failure to rare cases of enlarged kidneys that are detected in utero. The identity of the gene that is mutated in patients with ADPKD explains part of this phenotypic variability, so that patients with a mutation in PKD1 have earlier-onset ESRD, lower glomerular filtration rate (GFR) and larger kidney volumes than patients with a mutation in PKD2 (REFS). Sex is increasingly recognized as important to the outcome of renal disease in patients with ADPKD - in general, renal disease is substantially more severe in men than in women. However, >80% of patients with ADPKD and severe polycystic liver disease (PLD) are female, suggesting that hormonal differences might influence disease severity. The role of PKD1 allelic effects is becoming clearer, as a considerable proportion of in-frame PKD1 mutations are incompletely penetrant (hypomorphic) and result in ESRD later in life, lower GFR and smaller kidneys than with more penetrant alleles. However, genic or allelic effects do not seem to be important for the development of severe PLD in patients with ADPKD.

Mutational inactivation of both alleles of PKD1 or PKD2 is thought to cause embryonic lethality in humans (as in mice); however, patients with biallelic mutations who are homozygous or compound heterozygous, with at least one weak PKD1 or PKD2 hypomorphic allele (that is, with a reduced level of activity or expression), do survive. Biallelic mutations cause rare severe cases of onset of ADPKD in utero. A mouse model mimicking the hypomorphic PKD1 R3277C allele shows the association of the dosage of functional PC1 to disease severity. Digenic patients with ADPKD (that is, those with mutations in both PKD1 and PKD2) have more severe disease than monogenic family members, but digenic mutations are not lethal in humans. The combination of an ADPKD allele with an allele of another cystogene, such as HNF1B, may also exacerbate the renal disease phenotype.

At least 10-15% of families with ADPKD have no family history of the disease, suggesting that de novo mutations occur at a considerable rate, and intrafamilial variability in this case can be explained by mosaicism, in which the proportion of cells that carry the mutation and those that contain the wild-type allele can differ substantially. Mosaicism can be more reliably detected by next-generation sequencing (NGS)-based approaches than by conventional sequencing owing mainly to the superior sequencing depth in NGS.

Finally, studies of twins and those that analysed inter-familial and intrafamilial variability in ADPKD severity suggest that other genetic factors contribute substantially to the variability in the severity of renal disease, although, to date, the identity of these other genetic factors is unknown.

Cyst formation.

The cysts in patients with ADPKD are fluid-filled focal outgrowths from the renal epithelium, which arise in a minority (~1%) of nephrons and eventually detach when the amount of functional PC1 or PC2 drops below a critical threshold level. The polycystin proteins localize to the apical and basolateral plasma membrane, adherens junctions, desmosomes, focal adhesions and the primary cilium and are also secreted in microvesicles. In addition, PC2 is localized to the ER and mediates Ca ²⁺ release from this organelle. The polycystin proteins form multimeric protein complexes that modulate several signalling pathways, such as Ca ²⁺, cAMP, mechanistic target of rapamycin (mTOR), WNT, vascular endothelial growth factor (VEGF) and Hippo signalling. Consequently, numerous cellular changes have been observed in cyst-lining cells, including alterations in apical-basal polarity, planar cell polarity (PCP), increased extracellular matrix production and cellular metabolism, involving essential cellular functions such as fluid transport, proliferation, apoptosis, cell adhesion and differentiation ().

However, as PKD progresses, the molecular alterations in the kidneys are increasingly the consequence of secondary events that disrupt the network of signalling pathways. Reduced Ca ²⁺ influx, increased cAMP levels and aberrant RAS-RAF-ERK activation in renal epithelial cells are important mediators of cyst growth. which is further sustained by increased growth factor signalling. For example, increased levels of epidermal growth factor receptor (EGFR) and its mislocalization to the apical surface of cystic epithelial cells, together with the presence of the ligands EGF and transforming growth factor-α (TGFα) in cyst fluid, probably promote tubular epithelial cell proliferation. Other mechanisms that might be involved in cyst growth include altered signalling through G proteins, mTOR, phosphoinositide 3-kinase (PI3K)-AKT, AMP-activated protein kinase (AMPK), Janus kinase 2 (JAK2)-signal transducer and activator of transcription 1 (STAT1; or STAT3 or STAT6), nuclear factor of activated T cells (NFAT) and nuclear factor-κB (NF-κB). In addition, cyst expansion is accompanied by changes in cellular metabolism - increased glucose consumption that is indicative of ATP synthesis through aerobic glycolysis, and impaired fatty acid oxidation, seem to be additional features of ADPKD. Cysts can induce stress (presumably mechanical) on neighbouring nephrons, resulting in apoptosis of renal epithelial cells and thereby locally increasing the likelihood of cyst formation.

The polycystin complex localized in the primary cilium was initially thought to transduce extracellular fluid flow-generated shear stress into a cellular Ca ²⁺ signal, but subsequent studies suggested that although polycystin proteins induce local changes in ciliary calcium concentration through their channel function, global cytoplasmic calcium levels are not substantially altered. Intriguingly, the engineered loss of cilia ameliorates the cystic phenotype in Pkd1-mutant mice or Pkd2- mutant mice, suggesting that, in healthy kidneys, the polycystin proteins inhibit a cilia-regulated cystogenic signalling pathway that controls renal epithelial cell proliferation.

However, the function of the polycystin proteins at other subcellular locations should not be underestimated. Simultaneous ablation of Pkd1 and Itgb1 (which encodes β1 integrin) in mice resulted in inhibition of Pkd1 ablation-dependent cystogenesis and suppression of fibrosis, suggesting that PC1 represses signalling that regulates the crosstalk between the extracellular matrix and integrins. Although a direct association between PC1 and β1 integrin has not been detected, PC1 interacts with the cytoskeletal adaptor proteins vinculin and paxillin, which are essential for integrin signalling through focal adhesion complex proteins, such as focal adhesion kinase (FAK) and SRC. The accumulation of the extracellular matrix and the recruitment of inflammatory cells can already be observed at early stages of the disease. In particular, M1 and M2 macrophages are important contributors to disease progression. Macrophages and interstitial fibroblasts also produce cytokines, and abnormal cytokine-mediated crosstalk between renal epithelial cells and inflammatory cells results in a positive feedback loop of increasing fibrosis ().

In addition to altered cell-matrix interactions, the cell-cell junctions in cyst-lining epithelia are also abnormal. The abnormal composition and localization of adherens junctions and desmosomes in ADPKD suggest that the polycystin proteins regulate the dynamics of cell-cell adhesions to reduce their mechanical strength and allow cytoskeletal remodelling in ADPKD.

As a consequence, the integrity of apical-basal polarity and PCP is compromised in cystic epithelial cells. However, although disruption of PCP signalling results in inaccurate control of tubule diameter, it is not cystogenic. These data suggest that PKD mutations do not disrupt PCP signalling but instead act independently of and in parallel with PCP signalling to affect oriented epithelial cell division.

Overall, cystic epithelia often have a partially de-differentiated phenotype, suggesting that mutations in the PKD genes result in cells reverting to a developmental pattern of gene expression. Although the molecular mechanisms of polycystin regulation of various signalling pathways at different subcellular locations are not fully understood, this network of signalling pathways seems to be crucial for establishing and maintaining a differentiated renal epithelium.

Histopathological changes.

Epithelial cell proliferation, abnormal fluid secretion and excessive extracellular matrix deposition are the major characteristics of cystic epithelial cells. These changes are accompanied by alterations in the pericystic blood and lymphatic microvas-culature. Most cysts detach from the tubules from which they form and fill with fluid by transepithelial secretion. Cyst enlargement also compresses the surrounding nephrons, interstitium and vasculature. The obstructed nephrons eventually form atubular glomeruli and apoptotic proximal tubules.

These events are accompanied by the production of chemokines, cytokines and growth factors by epithelial cells, interstitial fibroblasts and inflammatory cells, such as macrophages. Abnormal cytokine-mediated crosstalk between epithelial and inflammatory cells promotes more inflammation and fibrosis, new cyst formation and disease progression, which result in massively fibrotic kidneys at end-stage disease (). Increased inflammation is probably an early event in disease progression, and the selective depletion of macrophages in the kidneys of a Pkd1 mouse model resulted in considerable amelioration of the cystic phenotype and improvement in renal function. Macrophage migration inhibitory factor (MIF) is an important pro-inflammatory cytokine in PKD, as deletion of Mif delayed cyst growth and improved renal function in Pkd1 -knockout mice.

Extrarenal pathology.

Patients with ADPKD also have cardiovascular abnormalities, including hypertension, left ventricular hypertrophy, aortic root dilatation, arterial aneurysms, heart valve abnormalities and intracranial aneurysms (ICAs) (reviewed elsewhere). Numerous lines of evidence suggest that the vascular and cardiovascular defects are directly related to reduced expression of the polycystin proteins (haploinsufficiency) in the endothelial cells and vascular smooth muscle cells (VSMCs) of most blood vessels, including the aorta and cerebral arteries. Indeed, the risk of cerebral aneurysms is higher in families with a positive family history of ADPKD than those without, probably because of modifying genes. The functions of PC1 and PC2 in the vasculature indicate that they have a crucial role in mechanosensation. In endothelial cells, the proteins are involved in fluid-shear stress sensing, thereby regulating calcium signalling and NO release. NO released by endothelial cells affects vasodilatation in response to increased blood flow. In VSMCs, the polycystins regulate pressure sensing by modulating the activity of the stretch-activated cation channels and myogenic contraction. A loss of myogenic tone may contribute to aneurysm formation owing to an increase in arterial wall stress. Finally, studies of haploinsufficient and hypomorphic models of ADPKD have shown that vascular changes are associated with a reduction of the levels of polycystin proteins.

The PKD genes are expressed in a wide range of tissues beyond the kidney, and their expression is developmentally regulated in most of these tissues. Accordingly, other extrarenal manifestations can occur, including cysts in the pancreas, seminal vesicles and the arachnoid membrane, in patients with ADPKD. Although patients with a single or those with more than one mutant PKD allele usually have relatively restricted disease phenotypes (that is, cysts or manifestations in only a few organs), complete knockout of Pkd1 or Pkd2 in mice results in embryonic lethality that is associated with a wide range of abnormalities, including: severely cystic pancreas, kidneys and liver; cardiac abnormalities; vascular defects (such as oedema and vascular leakage); craniofacial defects; bone defects; and, rarely, polyhydramnios (excess amniotic fluid). Tissue-specific Pkd1 or Pkd2 disruption results in hydrocephalus and lymphatic abnormalities in mice. The species-specific differences in ADPKD phenotypic severity suggest that the levels of polycystin proteins in most human tissues do not drop below a critical threshold or that when this happens, the affected cells might undergo apoptosis.

Experimental models.

To gain insight into the disease mechanisms and pathogenesis of ADPKD, various mouse models have been genetically engineered, including inducible, conditional knockout mice and mouse models with hypomorphic or hypermutable alleles of Pkd1 or Pkd2, which are extremely useful as ablation of Pkd1 or Pkd2 results in embryonic lethality and heterozygous mice develop only very mild disease, even in old age. These models are characterized by the age of disease onset, the progressiveness of the disease, the nephron segment that is affected, the number of affected nephrons, whether cyst formation is synchronized or unsynchronized and the extent of renal fibrosis and inflammation. These models enable step-by-step analysis of the pathogenesis of ADPKD and have provided valuable mechanistic insights into the early stages and the later, progressive stages of the disease. Findings in tissues from mouse models of early disease are complementary to those in renal tissues from patients with ADPKD, as the kidneys are usually removed from patients with the progressive stages of ADPKD or ESRD. Examples of the value of animal models include their role in highlighting the difference in the severity of renal disease observed when Pkd1 is inactivated during renal development compared with after the kidneys have formed. In addition, renal damage was shown to increase the severity of PKD in haploinsufficient mice. Finally, hypomorphic models have shown that polycystic kidneys can develop when polycystin function is reduced but not eliminated.

ARPKD

Genes and proteins.

The polycystic kidneys and congenital hepatic fibrosis (CHF) observed in ARPKD suggest that terminal differentiation of the renal collecting ducts and intrahepatic biliary ducts is disordered in this disease. Histological analysis has revealed that the changes in the liver that are invariably present from early embryonic development in patients with ARPKD are characterized by defective remodelling of the ductal plate with CHF and biliary duct ectasia, defined as ductal plate malformation (DPM; ), which also occurs frequently in other cilia-related disorders (ciliopathies), such as nephronophthisis, Joubert syndrome and Bardet-Biedl syndrome, some ofwhich may have an ARPKD-like phenotype. Different types of variants in PKHD1 (6p12.3-12.2), such as missense and truncating mutations, are responsible for most cases of ARPKD (discussed further in the Diagnosis section).

The mRNA of PKHD1 is alternatively spliced to produce multiple transcripts. The longest transcript encodes a 4,074-residue protein comprising a single transmembrane domain, an extensive extracellular N-terminal domain and a short C-terminal cytoplasmic tail (). Fibrocystin localizes to the primary cilium and to other cellular compartments and is targeted to the ciliary membrane by a specific motif in its C terminus. In addition, similar to Notch, fibrocystin is proteolytically cleaved to release the cytoplasmic tail, which translocates to the nucleus and presumably regulates downstream target genes. Although this remains to be conclusively established, it is possible that the C-terminal tail of fibrocystin regulates the expression of genes that encode proteins that drive cyst formation.

In addition, mutations in the gene encoding the ciliary transition zone protein DAZ-interacting protein 1-like protein (DZIP1L) have been described in some pedigrees in which the affected children had clinically moderate ARPKD and no evidence of mutations in PKHD1 (REF.; C.B., unpublished data). DZIP1L is a 767-residue soluble zinc-finger protein that, similar to PC1, PC2 and fibrocystin, localizes to centrioles and the distal end of basal bodies. DZIP1L interacts with septin 2 (SEPT2; in the septin ring), a protein that is implicated in the maintenance of the periciliary diffusion barrier at the ciliary transition zone. Consistent with a defect in the diffusion barrier, the localization of PC1 and PC2 to the ciliary membrane is compromised in DZIP1L-mutant cells. Diseases with symptoms similar to those in ADPKD and ARPKD might also be caused by mutations in other genes (reviewed in detail elsewhere). Of note, mutations in PKD1 and PKD2 can also be inherited in a recessive manner (homozygous or compound heterozygous) with at least one weak PKD1 or PKD2 hypomorphic allele; these patients can present with an ARPKD-like phenotype.

Finally, PKD (mimicking ARPKD or ADPKD) with hyperinsulinie hypoglycaemia was described in 11 pedigrees and was linked to biallelic mutations (including a specific promoter mutation) in phosphomannomutase 2 ( PMM2). PMM2 is a key enzyme in N-linked glycosylation, and recessive mutations in PMM2 are usually associated with congenital disorder of glycosylation type 1a, which has a severe, pleiotropic phenotype.

Determinants of disease severity.

Efforts to assess geno-type-phenotype correlations for PKHD1-linked ARPKD have been hampered by multiple allelism (that is, the presence of many different mutations in the same gene) and the high incidence of different compound heterozygotes (that is, the presence of two different mutant alleles at a single locus). However, genotype-phenotype correlations have been made for the type of mutation instead of the site of individual mutations. Allelic effects are known; for example, patients with two truncating mutations in PKHD1 often have severe disease that is usually lethal (although a few exceptions have been described) and surviving patients typically have at least one inframe mutation. These data indicate that many missense mutations do not completely abrogate PKHD1 function. Notwithstanding, some missense mutations in PKHD1 result in disease that is as severe as that resulting from truncating mutations. No substantial clinical differences have been observed between patients with two missense mutations and patients with a truncating mutation in trans; thus, the milder mutation seems to define the disease severity. Substantial intrafamilial variability among a considerable number of siblings indicates that other genetic and environmental factors also influence the disease phenotype.

The clinical course in patients and siblings with DZIP1L mutations described above was invariably moderate. Although the clinical manifestations in all of these patients were initially detected prenatally or during early childhood, none of the patients died perinatally. To date, the data are consistent with the idea that the type or location of the mutation in DZIP1L does not determine the severity of the clinical course. Patients who have missense mutations in both parental DZIP1L alleles have a phenotype comparable to that of patients who have two truncating DZIP1L alleles. Although genetic screening of a large number of patients who died perinatally has not been carried out, in view of homozygous truncating mutations in two patients, we hypothesize that it is unlikely that DZIP1L mutations play a major role in this cohort of mostly severely affected patients. This hypothesis is consistent with the birth of homozygous Dzip1l-mutant outbred mice at the expected Mendelian frequencies. However, the identification of additional families with DZIP1L mutations is required to draw firm conclusions.

Cyst formation.

ARPKD cysts arise predominantly from the distal tubules and collecting ducts, but the detailed mechanisms of cyst formation are only poorly understood. Fibrocystin is expressed postnatally predominantly in the kidneys, liver and pancreas, and as mentioned earlier, fibrocystin localizes to the apical membranes as well as to primary cilia, especially at the basal body and the mitotic spindle in renal tubular cells and biliary epithelial cells. DZIP1L is widely expressed and is localized primarily to centrioles and the distal end of basal bodies. Although little is known about the molecular functions of fibrocystin and DZIP1L, fibrocystin has been shown to interact with PC2 within the PC1-PC2 complex. In addition, as in ADPKD, the cAMP, MYC and mTOR signalling pathways are activated in ARPKD and thus represent potential targets for directed therapeutic intervention.

Experimental models of ARPKD.

To date, multiple Pkhd1-based models of ARPKD have been described, which were primarily generated by gene-targeting methods in mice. Although an ARPKD-like liver phenotype is invariably present in all of these mouse models, a renal phenotype is often absent, and when present, it is a mild, slowly progressive lesion that typically involves the proximal tubules rather than the collecting ducts. Interestingly, several models also have a severe pancreatic ductal phenotype, whereas clinically significant pancreatic disease in patients with ARPKD is quite rare. The mechanism that underlies the mild renal phenotype in these animal models remains unclear. However, as genetic background seems to have a major effect on renal pathology, genetic modifiers likely modulate renal disease. In the PCK rat, which arose owing to a spontaneous mutation in Pkhd1 (REF.), the hepatic phenotype is very similar to that in ARPKD, whereas the slowly progressive renal cystic disease in this model more closely resembles the renal cystic lesions in ADPKD than in ARPKD. Introgression of the Pkhd1 mutation in the PCK rat into a different background ameliorated the renal but not the hepatic phenotype, again suggesting that genetic factors modulate the severity of the renal cystic phenotype.

Consistent with the extensive phenotypic variability observed in experimental models of ARPKD, Dzip1l wpy/wpy mice (which were identified in an N-ethyl-N-nitrosourea-induced mutagenesis screen and contain a nonsense mutation in Dzip1l) display a number of embryonic morphological defects, including limb and craniofacial defects, in addition to cystic kidney disease and hepatobiliary DPM. The amelioration of the craniofacial phenotypes by crossing Dzip1l wpy/wpy mice with an outbred strain suggests that at least some of the phenotypic differences with the human ARPKD may be due to genetic background effects. Tissue-specific changes in the expression of genes involved in Hedgehog signalling, such as gene expression changes in the limb that are consistent with polydactyly, were detected in Dzip1l wpy/wpy embryos.

Diagnosis, screening and prevention

ADPKD

Diagnosis.

ADPKD is a progressive disease in which renal cyst development begins in utero, although cyst initiation and enlargement continue throughout the patient's life. Cyst enlargement results in an exponential increase in total kidney volume (TKV; expressed relative to height (htTKV)) and often results in ESRD. Clinical symptoms, including early-onset hypertension, abdominal fullness and pain, haematuria and urinary tract infections (UTIs), are usually first observed decades (sometimes even in childhood) before the onset of renal insufficiency (the numerous manifestations of the disease are described in ).

Table 1 |

Urinary concentration defect

Up to 60% of children

Earliest manifestation of mild polyuria is often undetected

* 50-70% of patients prior to GFR decline
* Average age of onset is 30 years
* At least 20-40% of children

Screen children with family history of ADPKD from 5 years of age, then at 3-year intervals if negative for hypertension

50% of patients by 60 years of age

Mean age of onset of 56 years (truncating PKD1 mutations), 68 years (non-truncating PKD1 mutations) or 78 years (PKD2 mutations)

Abdominal or flank pain

>60% of adult patients

* Acute or chronic
* Multiple causes

Urinary tract infection

30-50% of adult patients

More common in women than in men

Renal cell carcinoma

<1% of adult patients

Risk not increased compared with the general population, but patients can present with systemic symptoms of cancer

ICA

* 8% of all adult patients
* 21% of adult patients with a family history of ICA

Screen if family history of subarachnoid haemorrhage or ICA, personal history of intracranial haemorrhage, individuals working in high-risk professions and before major elective surgery (including before transplantation)

Presymptomatic diagnosis can usually be made in at-risk family members (such as children or siblings of affected individuals) by abdominal imaging, and the presence of multiple bilateral cysts identifies affected individuals. Ultrasonography is the most common and least expensive imaging method, but CT or MRI can provide more quantitative data (that is, htTKV) of prognostic value (). As cyst development in ADPKD is related to age, and even genetically unaffected individuals can develop a few simple cysts as they age, criteria have been developed to define whether at-risk individuals are affected on the basis of number of cysts by age ().

Table 2 |

Imaging provides a less certain diagnosis in young adults owing to the late and only mild disease manifestation in some patients; therefore, in these cases and others, genetic analysis may be helpful to obtain a definite diagnosis ( BOX 1).

Box 1 |

In a young relative who is a potential kidney donor for a patient with autosomal dominant polycystic kidney disease (ADPKD), especially if one or two cysts are detected by imaging methods - to exclude genetically affected relatives.

In individuals with a negative family history - to establish a firm diagnosis or to test for mosaicism (note that at least 10-15% of families with ADPKD can be traced to a new (de novo) mutation).

In cases of polycystic kidney disease of unknown origin and a negative family history - to assess recurrence risk and for family planning.

In patients with very early-onset disease - to identify biallelic disease or other complex genetics.

In patients with mild disease - to establish whether the disease is genetic and its cause.

In patients who are starting treatment or are being considered for a clinical trial - to establish a firm diagnosis and help determine whether the disease is rapidly progressive.

In all patients with ADPKD - if treatment is fairly inexpensive and reliable, most patients can obtain a firm diagnosis and prognostic information.

Obtaining a genetic diagnosis of ADPKD is complex because of historical segmental intrachromosomal duplication of three-quarters of the PKD1 gene (at the 5′ end), which produced six pseudogenes that have up to 99% sequence homology with PKD1. Consequently, specialized screening of PKD1 is required because mutations are not always detected by whole-exome sequencing (WES). Traditionally, genetic diagnostic analysis has involved using PKD1 -specific long-range PCR fragments that exploit the rare sequence differences between PKD1 and the pseudogenes, followed by Sanger sequencing or NGS of the long-range products to identify mutations. However, newer sophisticated NGS methods that use specific capture workflows and in silico analyses or whole-genome sequencing (WGS) have been reported, and capture-panel-based approaches are now favoured for genetic diagnosis of ADPKD.

Furthermore, interpretation of the results of genetic diagnostic analysis is complicated not only by the PKD1 pseudogenes but also by the high level of allelic heterogeneity in PKD1 and PKD2, in which >1,900 different mutations have been described, and no single mutation accounts for >2% of the total patient population (ADPKD Mutation Database). A substantial proportion of PKD1 mutations are in-frame (~30%), and because this gene has >300 described neutral non-synonymous variants, determining whether a missense variant is pathogenic is not always straightforward. Inquiry of the ADPKD Mutation Database and the use of scoring algorithms together with contextual information from population databases (for example, the Genome Aggregation Database (gnomAD) and family studies can help determine the pathogenicity of these variants. In ~7% of ADPKD families, no mutation is detected; some of these families probably have mutations at the known PKD loci that were not detected (for example, deep intronic or regulatory mutations), including mosaic cases that are probably more common in patients with de novo mutations than is currently reported. In addition, further genetic heterogeneity is likely, as mutations in GANAB were identified as a cause of mild ADPKD, which represents ~0.3% of all cases, and DNAJB11 mutations cause a hybrid of ADPKD and ADTKD. Phenocopies of the ADPKD phenotype can also be due to mutations in HNF1B and in other genes, such as those associated with ADPLD that result in an ADPKD-like phenotype. Parental renal ultrasonography should be carried out for family members of children who have cystic kidney disease of unknown origin. However, the family history is often unremarkable because of de novo mutations and combinations of incompletely penetrant (hypomorphic) alleles.

Asymptomatic at-risk individuals <18 years of age are usually not screened but decide whether and when to be tested as an adult. The rationale for this recommendation is based on the current lack of disease-specific treatments for those individuals <18 years of age and, in the USA at least, problems can occur with obtaining medical insurance and with workplace issues, despite antidiscrimination legislation. When necessary, monitoring and treatment of arterial hypertension and UTIs in at-risk children are recommended. However, the recommended age of testing may change if therapies become available for those <18 years of age after the completion of clinical trials in children and teenagers. Treatment of young individuals (even children) before irreparable kidney damage has occurred might be particularly effective. Increasing evidence exists that important predictors of future cardiovascular events and mortality (such as left ventricular hypertrophy, biventricular diastolic dysfunction, endothelial dysfunction, increased carotid intima-media thickness and impaired coronary flow velocity reserve) are evident in children and young individuals with normotensive blood pressure and normal kidney function very early in the disease course and that patients might benefit from an early diagnosis.

Prognosis.

Identifying patients with rapidly progressing disease would facilitate selection for clinical trials and treatment. Separating patients into classes on the basis of age-related htTKV (the Mayo Classification), and exclusion of atypical patients, have been proposed as an efficient means to identify patients with the most rapidly progressing disease. Combining genic and allelic information with clinical indications (onset of hypertension at <35 years of age and/or first urological event at <35 years of age) has also enabled identification of a population with rapidly progressing disease (the PROPKD score, a prognostic algorithm to predict renal outcomes in patients with ADPKD on the basis of genetic and clinical data). European recommendations have highlighted a demonstrated rapid decline in GFR in younger patients and/or a recorded rapid increase in htTKV as a means to identify patients with rapidly progressing disease who are suitable for treatment.

Prenatal screening.

As ADPKD is an adult-onset disease, prenatal screening is not commonly carried out, but there is increasing interest in this procedure, especially from families with experience of early-onset renal disease or early ICAs. Of note, affected families with children with early-onset ADPKD have a high risk of subsequent children also having early and severe ADPKD, and this information should be shared with affected families. Preimplantation genetic diagnosis is available for ADPKD, including analysis of the duplicated PKD1 locus, and may be more commonly sought in the future.

ARPKD

Diagnosis.

ARPKD is phenotypically highly variable: at its most severe, ARPKD presents in utero, at birth or in infancy and is characterized by bilaterally enlarged, echogenic kidneys with poor corticomedullary differentiation, retained reniform contour and multiple tiny cysts that are confined to the distal tubules and collecting ducts (); presentation in older children, teenagers or young adults includes manifestations of portal hypertension or cholangitis; and moderate presentation is seen rarely in older adults with complications of liver disease or with renal manifestations, such as proteinuria, nephrolithiasis and renal insufficiency. Those patients who survive the perinatal period then transition from paediatric to adult care with internal medicine specialists. With the advent of NGS-based molecular diagnostic testing, it has become evident that mutations in various other genes, such as HNF1B and those associated with ADPKD and many ciliopathies, can produce a phenotype that mimics the symptoms in ARPKD.

Potter sequence consists of pulmonary hypoplasia, characteristic facies and spine and limb abnormalities and can be present in severe neonatal cases, with death from respiratory distress occurring in at least 20% of cases. Surviving infants can experience childhood ESRD as well as liver complications owing to CHF that worsens with age. Patients who present with ARPKD later in childhood or as adults are more likely to have complications of portal hypertension, whereas renal enlargement is less evident than in patients who present earlier. With advancing clinical course, the kidney structure might increasingly resemble the symptoms observed in ADPKD, including renal cysts that vary considerably in size and appearance, often accompanied by some interstitial fibrosis. However, in contrast to the persistent renal enlargement that occurs in ADPKD, in ARPKD the kidneys decrease in size as the amount of fibrosis increases.

A diagnosis of ARPKD is likely to be based on clinical imaging in severe neonatal or infantile cases on the basis of enlarged echogenic kidneys, a negative family history of PKD and a lack of additional features (such as central nervous system abnormalities, eye defects and/or polydactyly) that may suggest a syndromic ciliopathy. However, molecular diagnostic analysis is the gold standard for diagnosing this disorder, and a number of pheno-copying disorders or syndromes must be considered. Genetic testing can be particularly important in the diagnostic evaluation of patients with early-onset bilateral renal cystic disease. In older patients, CHF with or even without renal cysts may indicate ARPKD and molecular diagnostic analysis may help confirm the diagnosis.

The large size of the PKHD1 gene (12,222 bp coding sequence, 67 exons and spans ~470 kb) and a high level of allelic heterogeneity (~60% of mutations are inframe and 40% of mutations are truncating) complicate the molecular diagnosis of ARPKD. Some mutations in PKHD1 are more common than others and some are enriched in specific populations; for example, T36M is the most common mutation and accounts for ~10-15% of mutant alleles in European populations. Analysis of DZIP1L is much easier than for PKHD1, as it has a 2,301 bp coding sequence, 16 exons and spans only ~53 kb. Mutations in DZIP1L are a considerably rarer cause of ARPKD than PKHD1 mutations, perhaps in part owing to the larger size of PKHD1 compared with DZIP1L. Furthermore, limited data suggest that the genomic region encoding the N terminus of DZIP1L may be more susceptible to mutations, which is supported by in silico data that predict that pathogenicity scores decay towards the C terminus.

In practice, and reflecting the phenotypic overlap of ARPKD with syndromic ciliopathies as well as other forms of PKD, including ADPKD, screening a panel of genes is now often considered to be the gold standard for diagnostics. Advances in NGS now enable simultaneous analysis of a large group of genes in a single test at fairly low cost. We expect that single-gene testing will soon be the exception rather than the rule, especially for genetically heterogeneous disorders with a broad phenotypic spectrum such as PKD. However, at present, targeted NGS panel testing might be the most efficient diagnostic approach. Whichever primary strategy is chosen for PKD diagnosis, it should be able to detect copy number variations such as heterozygous deletions (for example, in HNF1B) and to cover complex genomic regions, such as PKD1.

Prognosis.

In accordance with autosomal recessive inheritance, the recurrence risk for subsequent pregnancies of parents of an affected child with ARPKD is 25%. Males and females are equally affected. By definition, heterozygous carriers should not show any clinical disease manifestation, but data suggest that individuals who are heterozygous for PKHD1 mutations have an increased risk of PLD and mild PKD. Other relatives (such as healthy siblings) or the affected patients themselves may seek genetic counselling and can usually be reassured of a very low risk (<1%) for ARPKD for their own offspring if their partner is not affected by ARPKD and has no family history of PKD.

Prenatal screening.

Many parents of children with ARPKD seek early and reliable prenatal diagnosis of subsequent children to guide future family planning. Frequently, patients with ARPKD are diagnosed by ultrasonography only late in pregnancy or at birth. However, fetal sonography at the time when pregnancies are usually terminated may fail to detect enlargement and increased echogenicity of the kidneys or oligohydramnios (deficiency of amniotic fluid) secondary to poor fetal urine output. Thus, an early and reliable prenatal diagnosis of ARPKD in at-risk families is feasible only by molecular genetic analysis. Prenatal diagnosis should be offered only to families for which there is an unequivocal diagnosis in an affected family member. However, prenatal molecular genetic analysis is usually done using chorionic villus sampling, which is an invasive procedure that is carried out quite late in pregnancy (no earlier than week 10-12 of gestation). Interested families should also be informed about the possibility of preimplantation genetic diagnosis with in vitro fertilization at some diagnostic centres. Preimplantation genetic diagnosis always requires a high degree of coordination between different medical specialists and a health assessment in advance. In the future, it might be possible to conduct non-invasive prenatal testing of the fetal genotype by screening a maternal blood sample.

When considering prenatal testing, medical and ethical implications require a careful review by attending physicians and the parents. These tests should be embedded in an ethical framework based on the principles of beneficence and respect for autonomy. Beneficence-based clinical judgements should be evidence-based (that is, they should be based on the best available evidence), and clinical strategies should be identified that are reliably expected to result in the greatest balance of benefits (that is, the protection and promotion of health-related interests) over clinical harms (that is, impairments of those interests). Respect for autonomy and the patient's perspective is another key issue in the context of perinatal genetic testing. The physician is obliged to respect the parents' values and beliefs, to respect their perspective on their interests and to implement only those clinical strategies that are authorized as a result of informed consent.

Management

ADPKD

ADPKD is a systemic disorder with renal manifestations and an increasing number of extrarenal manifestations (). Management of ADPKD was the subject of a report of a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference, Spanish and Kidney Health Australia-Caring for Australasians with Kidney Impairment (KHA-CARI) management guidelines and a Core Curriculum. Additionally, a classification of ADPKD disease severity into different classes (1A-1E) was developed on the basis of htTKV (which provides an accurate estimate of kidney cyst burden in ADPKD) and age. The classification stratifies patients on the basis of the rate of GFR decline and is useful in clinical trials to identify patients with rapid disease progression who might benefit most from therapy, as opposed to patients whose disease progresses slowly and who might not need therapy.

Lifestyle interventions to enhance hydration, limit dietary sodium and protein intake and maintain a healthy weight, as well as early detection and rigorous treatment of hypertension and possibly dyslipidaemia, might have a beneficial effect on the course of the disease. Patients with ADPKD often have a mild urinary concentration defect that usually goes undetected, which is consistent with the inappropriate antidiuresis that is observed in Pkd1 heterozygous mice. Plasma vasopressin and its precursor copeptin, which serves as a marker of vasopressin, may be increased in patients with ADPKD, and plasma copeptin levels correlate with the severity of ADPKD in cross-sectional studies and with the rate of disease progression in prospective studies. Increasing evidence has shown that the action of vasopressin on the kidneys may contribute not only to the progression of ADPKD but also to the progression of CKD in general. Additionally, two large studies on cyst and kidney growth (the CRISP study) and hypertension (the HALT study) in ADPKD have shown an association between dietary salt intake and the rate of progression of ADPKD. The CRISP and the Modification of Diet in Renal Disease (MDRD) studies suggested an association between low levels of high-density lipoprotein (HDL) cholesterol and faster rates of kidney growth or GFR decline, respectively, in patients with ADPKD. Experimental studies have shown that moderate food or caloric restriction substantially inhibits disease progression in orthologous mouse models of ADPKD, and high body mass index in patients with ADPKD is associated with a poor outcome.

Treatments that directly target cystogenic mechanisms (such as decreasing cAMP levels in cystic tissues) are now available. For example, the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) 3:4 clinical trial showed that the vasopressin receptor 2 antagonist tolvaptan slowed the rate of kidney growth and estimated GFR (eGFR) decline in patients with early ADPKD (age 18-50 years, estimated creatinine clearance ≥60 ml min ⁻¹); tolvaptan has received regulatory approval in Japan, Canada, the European Union, Switzerland and South Korea for the treatment of ADPKD in patients with rapidly progressive disease. In the USA, approval from the US FDA was deferred until further data are available on the potential benefits and risks of tolvaptan treatment. The Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) clinical trial showed that tolvaptan also slows the eGFR decline in later-stage ADPKD (age 18-65 years, eGFR 25-65 ml/min/1.73 m ²), and the FDA has now approved the therapy in the USA. In both the TEMPO 3:4 and REPRISE trials, clinically significant elevation of serum transaminases was detected in ~5% of patients who were treated with tolvaptan; therefore, strict instructions to regularly monitor liver enzymes are incorporated into the treatment regimen. Potential benefits and adverse effects of tolvaptan treatment should be considered before prescribing tolvaptan, and the treatment is also recommended only for patients with rapidly progressive disease.

In the ALADIN study on kidney and cyst growth, patients with ADPKD were randomly assigned to octreotide (a long-acting somatostatin analogue that also decreases cAMP levels) or placebo treatment groups, and a favourable trend of reduced TKV increase and eGFR decline was observed, although statistical significance was not reached and thus larger trials are required. DIPAK1 and LIPS are ongoing clinical trials to evaluate the effect of the somatostatin analogue lanreotide on disease progression in patients with ADPKD and stage 3 CKD or stage 2-3 CKD, respectively. Clinical trials of the mTOR inhibitors sirolimus and everolimus failed to show benefit despite encouraging results in animal models, which is probably owing to an inability to administer sufficient levels of these drugs to inhibit mTOR in the kidneys without causing systemic toxic effects. Pravastatin, an HMG-CoA reductase inhibitor, has shown promising results in slowing cyst growth in a small randomized clinical trial in children with ADPKD.

Hypertension.

A recent meta-analysis concluded that at least 20% of children with ADPKD have hypertension and that many of those children are undiagnosed and do not attend regular follow-ups. A recent retrospective multicentre study of ambulatory blood pressure monitoring even found a higher prevalence of hypertension in children with ADPKD. In this study, 31%, 42% and 35% of a cohort of 310 children with ADPKD (mean age 11.5 ± 4.1 years) were hypertensive during the daytime, the night-time or the entire 24-hour cycle, respectively. More than half of the patients (52%) lacked physiological nocturnal blood pressure dipping. Thus, children with a family history of ADPKD should be screened regularly for hypertension from the age of 5 years and at 3-year intervals when no hypertension is found. The HALT PKD placebo-controlled clinical trial examined the role of blockade of the RAAS in patients with early and advanced ADPKD. In patients with early ADPKD (15-49 years of age, eGFR >60 ml/min/1.73 m ²), rigorous blood pressure control (blood pressure target range 95/60 to 110/75 mmHg) was associated with slower rates of increase in TKV and renal vascular resistance and with a greater decline in left ventricular mass index (faster during the first 4 months and slower decline there-after), without an overall effect on eGFR, than standard blood pressure control (120/70 to 130/80 mmHg). Rigorous blood pressure control was not studied in patients with more advanced ADPKD (18-64 years of age, eGFR 25-60 ml/min/1.73 m ²) because it was considered to be detrimental in these patients. At both early and late stages of the disease, monotherapy with an angiotensin-converting-enzyme (ACE) inhibitor achieved good blood pressure control (<130/85 mmHg) in most patients. Therefore, ACE inhibitors (or angiotensin receptor blockers (ARBs)) are considered to be the first-line therapy for hypertension in ADPKD.

Pain.

At least 60% of patients with ADPKD eventually experience acute or chronic abdominal or flank pain of renal origin. Acute pain is often associated with kidney cyst haemorrhage, infection or nephrolithiasis (kidney stones). Chronic pain is usually attributable to cyst enlargement that causes kidney capsule stretching or to marked enlargement of the kidneys and/or liver that causes musculoskeletal back pain. Managing chronic pain can be challenging and requires a multidisciplinary stepwise approach with multiple strategies, including physical therapy interventions, pain medications, cyst sclerosis and laparoscopic cyst fenestrations and renal denervation procedures.

Cyst infection.

The triad of abdominal or flank pain and/or tenderness, fever and elevated erythrocyte sedimentation rate or C-reactive protein (CRP) should raise suspicion of cyst infection. Initial evaluation should include urinalysis, urine culture with antimicrobial susceptibility testing, blood culture and imaging with CT scan or MRI. When available, an ¹⁸ F-fluorodeoxyglucose (FDG)-PET scan is more sensitive than CT or MRI for detecting cyst infections. If a complex cyst (that is, a cyst that does not meet the diagnostic criteria of a benign simple cyst) is detected, aspiration of cyst fluid should be considered if clinically feasible and the fluid should be sent for microbiology studies. Treatment of cyst infections should include intravenous broad-spectrum antibiotics if the patient has systemic symptoms, followed by a transition to oral antibiotics that have good cyst penetration, such as ciprofloxacin or other quinolones (total duration of antibiotic treatment should be at least 4 weeks). If the fever persists unabated for >72 hours, repeat imaging should be obtained to exclude complications that may require intervention (for example, perinephric abscess or urinary tract obstruction). Infected cysts >5 cm may be resistant to antibiotic therapy and require percutaneous or surgical drainage. Perinephric abscess requires prolonged intravenous antibiotic therapy and drainage should be considered. Nephrectomy is rarely needed but may be considered in cases of perinephric abscess or emphysematous pyelonephritis that are resistant to drainage and/or antibiotic therapy.

Renal cell carcinoma.

A high index of suspicion is required to make the diagnosis of renal cell carcinoma (RCC) in the rare cases when a tumour develops in a polycystic kidney, as RCC does not occur more frequently in ADPKD than in other renal diseases. Rapid growth of a complex cyst, a solid mass on ultrasonography, speckled calcifications on CT imaging, contrast enhancement, tumour thrombus and regional lymphadenopathies on CT or MRI scans should raise suspicion of RCC. Fever and systemic symptoms (anorexia, fatigue and weight loss) are frequent presenting symptoms. Nephronsparing interventions should be used whenever feasible and safe.

ESRD.

Kidney transplantation is the optimal kidney replacement treatment and the results in ADPKD patients are better than in the general ESRD population. Given the natural course of the disease, preemptive transplantation can be planned and is associated with better outcomes. Radical nephrectomy for space considerations is carried out in 20-25% of patients with ADPKD and may be done before, at the time of or several months after the transplantation. During the first year following a successful kidney transplantation, the volume of the native polycystic kidneys decreases by 30-40% for reasons that are unclear but might include reduced blood flow and resolution of uraemic factors that stimulate renal growth. Indications for nephrectomy also include recurrent and/or severe infection, bleeding, intractable pain, symptomatic nephrolithiasis and suspicion of kidney malignancy. Hand-assisted laparoscopic nephrectomy is less invasive than an open approach and the preferred timing varies between centres.

Although ADPKD is not a contraindication for peritoneal dialysis, it is less commonly used than haemo-dialysis given the challenge of accommodating a large volume of peritoneal dialysate and an increased risk of abdominal wall hernias. In haemodialysis treatment, patients with ADPKD may have an increased risk of aneurysmal dilatation of arteriovenous fistulas.

Hepatic cysts.

Surgical interventions for severe PLD should target symptom alleviation and improvement of QOL and should be tailored to the characteristics of individual patients and to the natural history of PLD. Surgical options include percutaneous aspiration and sclerosis with ethanol or other agents, deroofing of cysts laparoscopically or by open surgery and combined liver resection and cyst fenestration. The latter procedure should be reserved for patients with severe symptomatic PLD and a liver anatomy that allows the preservation of at least two contiguous liver segments with adequate hepatic venous drainage. Transcatheter arterial embolization results in only a modest volume reduction and is associated with substantial morbidity and mortality. Liver transplantation is considered for patients when partial liver resection is not feasible. Somatostatin analogues, such as octreotide and lanreotide, can reduce liver cyst volume.

Liver cyst infections are a common complication of PLD and are diagnosed, evaluated and managed similarly to infected kidney cysts. Diverticular disease and ascending cholangitis should be considered as a possible source of liver cyst infections. The presentation of ascending cholangitis is characterized by cholestasis with elevation of conjugated bilirubin. Some patients may experience recurrent episodes of cholangitis that may be difficult to treat, sometimes requiring monthly rotating antibiotics to prevent recurrences. Endoscopic sphincterotomy may increase the risk of recurrent cholangitis and should be avoided if possible. It is important to recognize that mild dilatation of the extrahepatic common bile duct can be observed in up to 40% of patients with ADPKD and should not lead to an unnecessary and dangerous sphincterotomy.

Intracranial aneurysms.

ICAs are detected in ~8% of patients with ADPKD, which is approximately fivefold higher than in the general population but is further increased (approximately threefold higher) in patients with a relative who has had an ICA.

The rupture of ICAs is associated with a mortality of up to 50% and a mean age at rupture of 40 years, which is lower than in the general population. Rupture usually presents as sudden onset of a severe headache (described as a thunder clap headache). Increased size, posterior location, family history of ICAs and a personal history of subarachnoid haemorrhage are potential risks for rupture. The management of unruptured ICAs is the same as that in the general population.

Given the frequency of ICAs in patients with ADPKD and that they increase morbidity and mortality risk, whether patients with ADPKD should undergo presymptomatic screening for ICAs has been intensely debated and universal consensus has not been reached. The majority of ICAs that were detected by presymptomatic screening in patients with ADPKD (which is generally carried out using magnetic resonance angiography (MRA)) are <7 mm in diameter and are in the anterior circulation (80-90% of cases), which in the general population have a very small risk of rupture. Few longitudinal studies of asymptomatic, unruptured ICAs in patients with ADPKD have been carried out, but the few that have suggest that their natural history is not different from that of ICAs in the general population. Accordingly, although we do not recommend presymptomatic screening for all patients with ADPKD, screening might be appropriate in patients with a family history of aneurysmal rupture owing to the higher prevalence of unruptured ICAs and possible increased risk of rupture. Screening may also be appropriate in patients with ADPKD who have a family history of ICAs and a personal history of intracranial haemorrhage, as well as in individuals in high-risk professions such as pilots and before major elective surgeries. Given the substantial risk of intervention, it is our opinion that treatment is not usually recommended for ICAs <7 mm in size; the frequency of follow-up MRAs for smaller ICAs depends on information about stability. If screening is negative, rescreening of patients with good life expectancy at 5-year intervals seems reasonable in our opinion. MRA for the detection of ICAs does not require administration of gadolinium and is preferable to CT angiography (CTA), especially in patients with reduced eGFR to avoid iodinated contrast.

ARPKD

In the most severe cases of ARPKD, poor urine output in utero results in oligohydramnios (deficiency of amniotic fluid) and Potter sequence. The ARPKD presentation at birth may be dominated by respiratory difficulties from pulmonary hypoplasia and/or from restrictive disease caused by massive kidney enlargement. In patients with respiratory insufficiency, the cause should be identified and aggressive resuscitative measures, including artificial ventilation if needed, should be implemented. In some severe cases, unilateral or bilateral nephrectomies may be considered, although the evidence to support this approach has been questioned. In patients who survive infancy, renal function may improve or remain stable for many years and slowly progress to renal failure only later in life as the kidneys develop macroscopic cysts and interstitial fibrosis, and the size ofthe kidneys relative to body mass often decreases.

Electrolyte, nutritional and growth abnormalities.

ESRD.

For infants with ESRD, peritoneal dialysis or haemodialysis can be used. Renal transplantation is limited by body size, but in centres that are well experienced in paediatric surgery, it can be carried out even in small children with a minimum weight of 7 kg. Rejection rates and survival beyond 3 years of age are not different from patients with most other renal diseases who undergo transplant surgery. Biliary sepsis can cause mortality in patients with ARPKD after renal transplantation.

Congenital hepatic fibrosis.

Combined kidney and liver transplantation has been advocated for selected patients with ESRD who have substantial bile duct dilatation and episodes of cholangitis. In addition to primary hyperoxaluria, ARPKD can certainly be considered an indication for combined liver and kidney transplantation during childhood. The best timing and strategy for combined transplantation is still a matter of debate and usually requires decision-making based on individual circumstances.

Quality of life

In the personalized medicine approach, it is no longer sufficient to treat the disease - instead, clinicians must treat their patients. Consequently, disease management paradigms should include biological, physical and psychological assessments, which seems to be particularly important for patients with multifaceted diseases such as ADPKD and further underscores the importance of including patient-reported outcomes in routine clinical care. In parallel, sensitive and appropriate kidney disease measures should be developed alongside other established tools to assess the burden of ADPKD in an individualized, personalized manner. Health-related QOL (HRQOL), which encompasses physical and mental health, social issues as well as pain and discomfort, facilitates patient-centred care and encourages shared decision-making among medical professionals and patients. The specific issues of QOL have not been systemically studied in patients with ARPKD or their families; accordingly, we focus on only ADPKD.

ADPKD affects the biological, physical and psychological aspects of patient QOL. For example, physicians underestimate the effect of renal pain in patients with ADPKD, despite its high prevalence in patients with chronic kidney diseases. Pain and abdominal fullness, which are both common symptoms of ADPKD, are often associated with lower eGFR. Furthermore, pain is independently associated with clinical depression, and although evidence exists that depression is common among patients with ADPKD, studies that explicitly address the treatment of depression in patients with ADPKD are lacking. Accordingly, HRQOL assessment might help guide treatment decisions. Indeed, HRQOL scores have been shown to predict risk of increased hospitalization and mortality in patients with chronic kidney diseases. However, only a limited number of HRQOL studies of patients with ADPKD have analysed possible correlations between disease progression, psychosocial burden and their effect on daily living.

Generic QOL measures (such as the 36-item Short Form Health Survey (SF-36)) are fairly insensitive, especially in patients with early-stage ADPKD. In a recent study of HRQOL in patients with ADPKD who encompassed all stages of the disease (from patients with early CKD to those on dialysis or undergoing renal transplantation), overall HRQOL was generally highest in patients with CKD stage 1-3, followed by renal transplant recipients, patients with stage 4-5 CKD and patients on dialysis. Progressive disease predominantly had an effect on physical health, whereas mental health varied less between patients with different stages of the disease.

A new self-administered patient-reported outcome questionnaire, the ADPKD Impact Scale (ADPKD-IS), which consists of 14 items representing 3 conceptual domains (physical, emotional and fatigue) and 4 additional questions, was developed on the basis of the information (see below) of 1,674 patients worldwide. The ADPKD-specific conceptual framework (a model representing concepts and themes to be measured and their relationships) in this questionnaire was created on the basis of information from patients and clinical experts about how ADPKD affected the general health, daily activities, physical or social activities, pain experience, urinary issues (such as urgency and frequency of urination as well as nocturia) and emotional well-being of patients. Scores on the physical, emotional and fatigue domains of the ADPKD-IS differed substantially between patients with stage 3b CKD versus those with stage 1 CKD at baseline.

Of note, effective treatment of ADPKD can improve HRQOL - a 1-year trial with octreotide resulted in modestly reduced liver volumes (4.95% ± 6.77%) and was associated with improvements in pain and emotional scales on the SF-36 (REF.). Perceived social support and the psychosocial impact of coping with a diagnosis of ADPKD were analysed in another cross-sectional study, which found that lower eGFR was associated with less perceived social support. Depression, increased kidney size and loss of a first-degree relative to ADPKD were identified as independent risk factors for increased psychosocial risk. Of note, women were more likely to be predisposed to poorer overall psychosocial well-being than men.

Given the genetic basis of ADPKD, patients are often faced with major psychological challenges related to the hereditary nature of the disorder and its potential effect on their family and offspring. 'Genetic guilt' may be the reason many patients hide their diagnosis from their spouse and family, even when these people are usually central to their emotional support network. Hidden genetic guilt substantially affects the psychosocial well-being of patients.

Outlook

Although the prospects for better outcome predictions and treatments have dramatically improved over the past decade, an incomplete understanding of the function of the polycystin proteins remains a substantial impediment to understanding the pathogenesis of PKD and developing rational therapies to treat these diseases. For ARPKD in particular, the limitations of experimental models and the paucity of biomarkers and imaging modalities to enable prediction of the disease course limit current efforts to design clinical trials to test the efficacy of potential new therapies.

Pathogenesis

The greatest challenge in research on PKD, and that which is likely to be of greatest benefit if overcome, is understanding the pathogenesis of PKD. Although the aetiologies of ADPKD and ARPKD are mostly understood, many questions about the pathogenesis of these diseases are still intensely disputed. For example, although PC2 is a TRP-like calcium channel, a definite role for Ca ²⁺ in the pathogenesis of ADPKD has not been established, and the role of PC2 as a chaperone for PC1 may be important. The role of somatic changes at the disease-causing locus in cystic epithelia, which are required for cyst initiation and, more importantly, for cyst expansion and/or persistence, is another highly debated area of research that would benefit from additional studies.

The ciliary basis of PKD pathogenesis has been the predominant hypothesis for >15 years, but studies have cast doubt on this hypothesis. The proposed ciliary localization (among others) of PC1, PC2, fibrocystin and DZIP1L and the observations that a loss of ciliary function or the abnormal ciliary composition in some syndromic ciliopathies cause PKD are the strongest evidence supporting the cilia hypothesis. However, the role of the polycystin complex in cilia is not clear; for example, the hypothesis that the polycystin complex functions as a mechanosensor in cilia is not supported by recent data. Indeed, despite a study suggesting that the polycystin complex is a WNT receptor, the function of the polycystin complex in healthy tissue seems far from resolved and this uncertainty remains a major impediment to understanding the pathogenesis of ADPKD. As discussed earlier, cilia certainly have a role in PKD, as concomitant ablation of Pkd1 and loss of cilia in mice results in less severe cystic disease than ablation of Pkd1 alone. Alternatively, separate cystic (polycystin complex-related) and proliferation pathways required for cystic growth are ciliary-based. In fact, the ciliary localization of PC1 has been questioned (a specific stimulus might be required for PC1 to get to the cilium), and other polycystin-like proteins (such as PKD1-like protein 1 (PKD1L1) and PKD2L1), rather than PC1 and PC2, might regulate ciliary Ca ²⁺ levels. In addition, conflicting data exist about whether calcium influx into the cilium is sufficient to activate a cytoplasmic calcium response.

Although a ciliary function has been proposed for both fibrocystin and DZIP1L, and genetic studies suggest that they are associated with the polycystin complex, the precise role of these proteins remains unresolved. That fibrocystin seems much more important for kidney tubule integrity in humans than in mice further complicates experimental resolution. The functions of PC1, PC2, fibrocystin and DZIP1L, or those of the cleavage products of these proteins, when secreted into urine in soluble form or in urinary extracellular vesicles exocytosed by the multivesicular body pathway, or even possibly from cilia, require further study. Other unresolved questions include whether the C terminus of PC1 (and fibrocystin) is cleaved and translocates to the nucleus, how much it contributes to the signalling by the polycystin complex and whether it is relevant for preventing PKD. Additionally, ciliary-based signalling, such as that mediated by sonic hedgehog, has also been suggested to be important in PKD, although its precise role in ADPKD and ARPKD is not clear.

Diagnosis and prognosis

Further research is necessary to improve the identification of patients who require treatment and especially the monitoring of treatment efficacy. It is widely accepted that current methods to monitor kidney function are not very useful for diagnosis in the early stages of disease when treatment is likely to be the most efficacious. Determination of htTKV by imaging is currently the best method to predict disease outcomes and to monitor treatment efficacy, and further quantitative image analysis of kidney composition is likely to improve its predictive and monitoring value. Research to identify potential biochemical biomarkers is still in the early stages, but with an easily accessible supply of urine from patients to monitor kidney function, it seems likely that this area of research is ripe for development. Together with the present genic and allelic predictive value of the germline mutation, better in silico analyses and cellular assays should enable the identity and penetrance of in-frame mutations to be more accurately predicted. Other genetic factors that are associated with disease progression (identified using genome-wide association studies, WES and WGS) are also likely to be of prognostic value and to improve our understanding of the pathogenesis of PKD.

Therapies

This is an exciting time for PKD studies, as the first drug specifically for the treatment ADPKD, tolvaptan, has received regulatory approval in many parts of the world. It seems likely that other treatments targeting signalling pathways downstream of PKD-causing genetic lesions, including inhibitors of cAMP generation (for example, somatostatin analogues such as octreotide), more effective inhibitors of mTOR activity in the kidneys (for example, rapamycin conjugates), remedying metabolic abnormalities (for example, by food restriction) and other therapies that were effective in rodent studies (for example, reducing inflammation or calcium signalling; reviewed elsewhere), are likely to be approved for human treatment in the next few years. There are prospects for combination treatments, and some of these therapies may also be effective in treating severe PLD. Furthermore, although the development of treatments that more directly target the basic defect (deficiency of PCI or PC2) in PKD has not been undertaken, evidence exists for other genetic diseases that this approach could be productive. These treatments could include chaperone treatment for some missense mutations, targeting nonsense mutations using translational readthrough-inducing drugs, boosting the levels of functional PC1 and somatic gene editing using CRISPR-Cas9 (REF.) to repair the underlying defect in the kidneys. To date, little progress has been made in developing treatments for ARPKD, but given the related disease mechanisms in ADPKD and ARPKD, there is the hope that at least some therapies for ADPKD might also be effective in treating ARPKD.

# data[].attributes.attachment_link.description
In patients with polycystic kidney diseases (PKDs), the kidneys contain multiple fluid-filled cysts, although other organs may also be affected (). Although PKD is inherited monogenically, it is phenotypically, genically and allelically heterogeneous.

# data[].attributes.headline
There is no cure, but we can slow the growth

# data[].attributes.subject
There is no cure, but we can slow the growth

# data[].attributes.body
There are two types of polycystic kidney disease: they are both genetic related disorders however,
Autosomal dominant: more prominent in adults

Autosomal recessive: more prominent in children.

# data[].attributes.headline
Lipoic Acid and Autosomal Dominant Polycystic Kidney Disease 

# data[].attributes.subject
Lipoic Acid and Autosomal Dominant Polycystic Kidney Disease 

# data[].attributes.body
There was a study done using a type of lipoic acid (ALA) daily to see if it could help treat the disease. There may be small side effects. It is important to evaluate the cognitive abilities, psychological health, and the quality of life early on within the disease. Nurses will be responsible for measuring blood levels, measuring blood pressures, performing common carotid ultrasounds, flow mediated dilation, and psychological and cognitive tests to make sure the entire study is going smoothly.

# data[].attributes.attachment_link.readable_text
Need Help Logging In to your Account?
You can reach the Information Desk : by calling 573-681-5888, by emailing helpdesk@lincolnu.edu or by Online Form .

Support hours:
Regular Hours: Monday-Friday 8:00 am - 5:00 pm
Summer Hours: Monday-Thursday 7:30 am - 6:00 pm

# data[].attributes.attachment_link.description
Need Help Logging In to your Account? You can reach the Information Desk : by calling 573-681-5888, by emailing helpdesk@lincolnu.edu or by Online Form . Support hours: Regular Hours: Monday-Friday 8:00 am - 5:00 pm Summer Hours: Monday-Thursday 7:30 am - 6:00 pm

# data[].attributes.attachment_link.title
Polycystic Kidney Disease - Yale Medicine Explains

# data[].attributes.headline
A video explaining some more interesting facts about PKD.

# data[].attributes.subject
A video explaining some more interesting facts about PKD.

# data[].attributes.body
Surprisingly, yes, in moderation of course. Not a good idea if a patient is on dialysis. Always a good idea to ask your doctor.

# data[].attributes.attachment_link.readable_text
When it comes to drinking alcohol, moderation is the key. Drinking too much alcohol-even for a completely healthy person-can cause heart disease, liver disease, high blood pressure and kidney disease, in addition to many other medical problems. Drinking too much alcohol can also impair judgment-and this could interfere with decision making related to remembering to take medicines and following fluid and diet guidelines.

Renal diets and alcohol

Moderate alcohol drinking may be okay for people with chronic kidney disease (CKD) who are not on dialysis. However, it's best to first check with your nephrologist or renal dietitian to find out if alcohol is safe for you. If you're able to drink alcohol safely, your healthcare team will advise you on the types and amounts that are right for you.

If you're on dialysis, drinking alcohol may be allowable, but it must be counted within your normal fluid allowance and diet, and medicines must be taken into consideration. Talk to your doctor or dietitian before you drink any alcohol.

For those with diabetes and CKD, alcohol may be safe to drink if you have your blood sugar level under control. After getting the okay to drink from your doctor or dietitian, it is recommended that you drink with food. Alcohol on an empty stomach can cause blood sugar levels to drop in those with diabetes. Additional ingredients in mixed drinks may add carbohydrate that must be considered. You will also have to fit alcohol into your meal plan.

Alcohol has no nutritional benefit, but it does have calories which can add up quickly. Take this into consideration when planning your daily menus.

Some medicines, both prescription and over-the-counter, may interact with alcohol. and cause the medicines not to work properly. There are other medicines that may cause your blood alcohol level to rise. Check drug labels and ask your pharmacist or doctor to review your medications to make sure alcohol will not be harmful with your medication.

Safe levels of drinking

The federal government's Dietary Guidelines for Americans defines moderate drinking as:

one drink per day for women and older people

two drinks per day for men

The limits are different for men and women, because men usually weigh more and alcohol is processed differently by the sexes. Women tend to have a stronger reaction to alcohol. One reason is that women have less water in their bodies, so the alcohol becomes more concentrated. The risk for alcohol-related diseases is also higher in women than in men.

The following count as one drink and each contains the same amount of alcohol:

12 ounces of beer or wine cooler

5 ounces of wine

1.5 ounces of 80-proof distilled spirits (whiskey, bourbon, scotch, vodka, gin, tequila, rum)

To drink or not to drink

Drinking alcohol can generally be done safely in moderation, even if you have CKD, polycystic kidney disease, end stage renal disease (ESRD) or diabetes. Take caution, however, if you have high blood pressure. Also, be aware of ingredients and nutrient content of the beverage you choose to drink. Always check with your doctor or renal dietitian to make sure it is safe for you to drink alcohol.

# data[].attributes.attachment_link.description
When it comes to drinking alcohol, moderation is the key. Drinking too much alcohol-even for a completely healthy person-can cause heart disease, liver disease, high blood pressure and kidney disease, in addition to many other medical problems. Drinking too much alcohol can also impair judgment-and this could interfere with decision making related to remembering to take medicines and following fluid and diet guidelines.

# data[].attributes.body
-In the United States about 600,000 people have PKD.
-PDK is the fourth leading cause of kidney failure.
-It is found in all races and occurs equally in men and women.
-It causes about 5% of all kidney failure.
-PKD may also cause cysts in their liver, pancreas, spleen, ovaries, and large bowel.

# data[].attributes.attachment_link.readable_text
What is polycystic kidney disease?

Polycystic kidney disease (also called PKD) causes numerous cysts to grow in the kidneys. These cysts are filled with fluid. If too many cysts grow or if they get too big, the kidneys can become damaged. PKD cysts can slowly replace much of the kidneys, reducing kidney function and leading to kidney failure.

How common is PKD?

In the United States about 600,000 people have PKD. It is the fourth leading cause of kidney failure. It is found in all races and occurs equally in men and women. It causes about 5% of all kidney failure.

What other organs besides the kidney are affected by PKD?

PKD can affect other organs besides the kidney. People with PKD may have cysts in their liver, pancreas, spleen, ovaries, and large bowel. Cysts in these organs usually do not cause serious problems, but can in some people. PKD can also affect the brain or heart. If PKD affects the brain, it can cause an aneurysm. An aneurysm is a bulging blood vessel that can burst, resulting in a stroke or even death. If PKD affects the heart, the valves can become floppy, resulting in a heart murmur in some patients.

What are the clues that someone has PKD?

Most people do not develop symptoms until they are 30 to 40 years old. The first noticeable signs and symptoms may include:

Back or side pain

An increase in the size of the abdomen

Blood in the urine

Frequent bladder or kidney infections

High blood pressure
High blood pressure is the most common sign of PKD. Occasionally, patients may develop headaches related to high blood pressure or their doctors may detect high blood pressure during a routine physical exam. Because high blood pressure can cause kidney damage, it is very important to treat it. In fact, treatment of high blood pressure can help slow or even prevent kidney failure.

Fluttering or pounding in the chest
About 25% of PKD patients have a so-called floppy valve in the heart, and may experience a fluttering or pounding in the chest as well as chest pain. These symptoms almost always disappear on their own but may be the first hint that someone has PKD.

How is PKD diagnosed?

Ultrasound is the most reliable, inexpensive and non-invasive way to diagnose PKD. If someone at risk for PKD is older than 40 years and has a normal ultrasound of the kidneys, he or she probably does not have PKD. Occasionally, a CT scan (computed tomography scan) and MRI (magnetic resonance imaging) may detect smaller cysts that cannot be found by an ultrasound. MRI is used to measure and monitor volume and growth of kidneys and cysts.

In some situations, genetic testing might also be done. This involves a blood test that checks for abnormal genes that cause the disease. Genetic testing is not recommended for everyone. The test is costly, and it also fails to detect PKD in about 15% of people who have it. However, genetic testing can be useful when a person:

has an uncertain diagnosis based on imaging tests

has a family history of PKD and wants to donate a kidney

is younger than 30-years old with a family history of PKD and a negative ultrasound, and is planning to start a family

Does everyone with PKD develop kidney failure?

No. About 50 percent of people with PKD will have kidney failure by age 60, and about 60 percent will have kidney failure by age 70. People with kidney failure will need dialysis or a kidney transplant. Certain people have an increased risk of kidney failure including:

men

patients with high blood pressure

patients with protein or blood in their urine

women with high blood pressure who have had more than three pregnancies

How is PKD treated?

At present, there is no cure for PKD. However, a lot of research is being done. Recent studies suggest that drinking plain water throughout the day and avoiding caffeine in beverages can slow the growth of cysts. Research is also helping us understand the genetic basis of PKD.

Studies also suggest that some treatments may slow the rate of kidney disease in PKD, but further research is needed before these treatments can be used in patients. In the meantime, many supportive treatments can be done to control symptoms, help slow the growth of cysts, and help prevent or slow down the loss of kidney function in people with PKD. These include:

careful control of blood pressure

prompt treatment with antibiotics of a bladder or kidney infection

lots of fluid when blood in the urine is first noted

medication to control pain (talk to your doctor about which over-the-counter medicines are safe to take if you have kidney disease)

a healthy lifestyle with regard to smoking cessation, exercise, weight control and reduced salt intake

drinking lots of plain water throughout the day

avoiding caffeine in all beverages

Should people with PKD take a special diet?

At present, no specific diet is known to prevent cysts from developing in patients with PKD. Reducing salt intake helps control blood pressure in PKD patients who have high blood pressure. A diet low in fat and moderate in calories is recommended to maintain a healthy weight. Speak to your doctor or a dietitian about other changes to your diet, such as avoiding caffeine.

Is exercise recommended for people with PKD?

Absolutely. However, exercises that are potentially harmful to the kidney, such as contact sports, should be avoided. It is important not to become too dehydrated during any physical activity.

Who is at risk for developing PKD?

PKD runs in families. It is an inherited disorder that is passed from parents to children through genes. Genes are the basic elements of heredity. At conception, children receive a set of genes from each parent. They determine many characteristics such as hair color and eye color. Genes can also determine the likelihood of developing a disease.

A genetic disease can happen if one or both parents pass abnormal genes to a child. This happens through something called dominant inheritance or recessive inheritance.

If one parent has the disease and passes an abnormal gene to the child, it is called dominant inheritance. Each child has a 50% chance of getting the disease. The risk is the same for every child, regardless of how many children develop the disease.

If both parents carry the abnormal gene, and both parents pass an abnormal gene to the child, it is called recessive inheritance. In this situation, every child has a 25% chance of getting the disease.

Are there different types of PKD?

Yes. The three main types of PKD are:

Autosomal Dominant PKD
(also called PKD or ADPKD)
This form of the disease is passed from parent to child by dominant inheritance. In other words, only one copy of the abnormal gene is needed to cause the disease. Symptoms usually begin between the ages of 30 and 40, but they can begin earlier, even in childhood. ADPKD is the most common form of PKD. In fact, about 90 percent of all PKD cases are ADPKD.

Infantile or Autosomal Recessive PKD
(also called ARPKD)
This form of the disease is passed from parent to child by recessive inheritance. Symptoms can begin in the earliest months of life, even in the womb. It tends to be very serious, progresses rapidly, and is often fatal in the first few months of life. This form of ARPKD is extremely rare. It occurs in 1 out of 25,000 people.

Acquired Cystic Kidney Disease
(also called ACKD)
ACKD can happen in kidneys with long-term damage and severe scarring, so it is often associated with kidney failure and dialysis. About 90 percent of people on dialysis for 5 years develop ACKD. People with ACKD usually seek help because they notice blood in their urine. This is because the cysts bleed into the urinary system, which discolors urine.

Should people with PKD have children?

Individuals with PKD who are concerned about passing the disease to their children may want to consult a genetics counselor to help them with family planning. Many university medical centers have this service.

Should women with PKD get pregnant?

Most of the women with PKD (80 percent) have successful and uneventful pregnancies. However, some women with PKD have an increased risk for serious complications for themselves and their babies. This includes women with PKD who also have:

high blood pressure

decreased kidney function

Women who have PKD with high blood pressure develop pre-eclampsia (or toxemia) in 40 percent of pregnancies. This is a life-threatening disorder for both the mother and baby, and it can develop suddenly and without warning. Therefore, all women with PKD, particularly those who also have high blood pressure, should be followed closely during their pregnancy by their doctor.

What if I have more questions?

If you have more questions, you should speak to your doctor. You can also get more information from:

Polycystic Kidney Disease Foundation
8330 Ward Parkway, Suite 510
Kansas City, MO 64114
(800) PKD-CURE
www.pkdcure.org

# data[].attributes.attachment_link.description
What is polycystic kidney disease? Polycystic kidney disease (also called PKD) causes numerous cysts to grow in the kidneys. These cysts are filled with fluid. If too many cysts grow or if they get too big, the kidneys can become damaged. PKD cysts can slowly replace much of the kidneys, reducing kidney function and leading to kidney failure.